Key facts
- Autonomize AI’s last known valuation is $121.0M (Jun 2025).
- It has raised $32.7M; the latest was Early Stage VC ($28.6M) in Jun 2025.
- Notable investors include Capital Factory, Tau Ventures, Singularity Capital, ATX Venture Partners, Asset Management Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Autonomize AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Autonomize AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Autonomize AI
Developer of artificial intelligence (AI) agents designed to automate and streamline administrative and clinical workflow processes in the healthcare industry. The company's platform uses artificial intelligence agents to manage utilization management, care management, claims processing, pharmacy workflows, and appeals handling, enabling healthcare payers, providers, life sciences organizations, and digital health companies to reduce administrative workloads and accelerate operational decision-making.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2021
- Employees
- 105
- Website
- autonomize.ai/
- Ownership
- Privately Held (backing)
Autonomize AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Autonomize AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Autonomize AI in its N-PORT filings yet. We sweep new filings monthly.